Newsroom Alerts

To opt-in for email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Thermo Fisher Scientific, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the email alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Thermo Fisher Scientific to send you the requested Email Alert updates.

* Required

News Details

View all news

Thermo Fisher Scientific Reports Second Quarter 2024 Results

07/24/2024

WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024.

Second Quarter 2024 Highlights

  • Second quarter revenue was $10.54 billion.
  • Second quarter GAAP diluted earnings per share (EPS) increased 15% to $4.04.
  • Second quarter adjusted EPS increased 4% to $5.37.
  • Continued to strengthen our industry-leading commercial engine and deepen our trusted partner status with customers to accelerate their innovation and enhance their productivity. In the quarter, we expanded our leading clinical trial supply services with a new ultra-cold facility in Bleiswijk, the Netherlands and a new state-of-the-art innovation lab at our site in Center Valley, Pennsylvania, to enable our pharmaceutical and biotech customers to accelerate the development of therapies and medicines. Also in the quarter, to support Indonesia’s growing investments in healthcare, scientific research, and renewable energy, we expanded our presence and capabilities in the country, further demonstrating our relevance to customers around the world.
  • Shortly after the quarter ended, we completed our acquisition of Olink, a provider of differentiated next-generation proteomic solutions. The addition of Olink’s technology extends our capabilities and further advances our leadership position in protein research, enabling our customers to meaningfully accelerate discovery and scientific breakthroughs while delivering on the promise of precision medicine.

“Our excellent execution enabled us to deliver another quarter of strong financial performance and share gain,” said Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific. “We continue to see the benefit of our proven growth strategy and the impact of our PPI Business System in our performance. Shortly after the quarter ended, we were also pleased to welcome our Olink colleagues to Thermo Fisher and are excited about the power of this new combination to better serve our customers and advance science.”

Casper added, “We have made very good progress through the halfway point of the year and are in a great position to deliver differentiated performance in 2024. We’ve further extended our industry leadership and positioned our company for an even brighter future.”

Second Quarter 2024

Revenue for the quarter declined 1% to $10.54 billion in 2024, versus $10.69 billion in 2023. Organic revenue was 1% lower and Core organic revenue growth was flat.

GAAP Earnings Results

GAAP diluted EPS in the second quarter of 2024 increased 15% to $4.04, versus $3.51 in the same quarter last year. GAAP operating income for the second quarter of 2024 grew to $1.82 billion, compared with $1.58 billion in the year-ago quarter. GAAP operating margin increased to 17.3%, compared with 14.8% in the second quarter of 2023.

Non-GAAP Earnings Results

Adjusted EPS in the second quarter of 2024 increased 4% to $5.37, versus $5.15 in the second quarter of 2023. Adjusted operating income for the second quarter of 2024 was $2.35 billion, compared with $2.37 billion in the year-ago quarter. Adjusted operating margin increased to 22.3%, compared with 22.2% in the second quarter of 2023.

Annual Guidance for 2024

Thermo Fisher is raising its full-year revenue and adjusted EPS guidance. The company is raising its revenue guidance to a new range of $42.4 to $43.3 billion versus its previous guidance of $42.3 to $43.3 billion. The company is raising its adjusted EPS guidance to a new range of $21.29 to $22.07 versus its previous guidance of $21.14 to $22.02.

Use of Non-GAAP Financial Measures

Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, organic revenue growth and Core organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Supplemental Information Regarding Non-GAAP Financial Measures.” The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release.

Note on Presentation

Certain amounts and percentages reported within this press release are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.

Conference Call

Thermo Fisher Scientific will hold its earnings conference call today, July 24, at 8:30 a.m. Eastern Daylight Time. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 023107. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under the heading “Financials”. A replay of the call will be available under “News, Events & Presentations” through Wednesday, August 7, 2024.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K, and subsequent quarterly report on Form 10-Q, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Condensed Consolidated Statements of Income (unaudited)

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

June 29,

 

% of

 

July 1,

 

% of

(Dollars in millions except per share amounts)

 

2024

 

Revenues

 

2023

 

Revenues

Revenues

 

$

10,541

 

 

 

 

$

10,687

 

 

 

Costs and operating expenses:

 

 

 

 

 

 

 

 

Cost of revenues (a)

 

 

6,106

 

 

57.9

%

 

 

6,323

 

 

59.2

%

Selling, general and administrative expenses (b)

 

 

1,687

 

 

16.0

%

 

 

1,673

 

 

15.7

%

Amortization of acquisition-related intangible assets

 

 

513

 

 

4.9

%

 

 

585

 

 

5.4

%

Research and development expenses

 

 

339

 

 

3.2

%

 

 

345

 

 

3.2

%

Restructuring and other costs (c)

 

 

77

 

 

0.7

%

 

 

183

 

 

1.7

%

Total costs and operating expenses

 

 

8,722

 

 

82.7

%

 

 

9,109

 

 

85.2

%

Operating income

 

 

1,820

 

 

17.3

%

 

 

1,578

 

 

14.8

%

Interest income

 

 

295

 

 

 

 

 

178

 

 

 

Interest expense

 

 

(354

)

 

 

 

 

(326

)

 

 

Other income/(expense) (d)

 

 

5

 

 

 

 

 

 

 

 

Income before income taxes

 

 

1,765

 

 

 

 

 

1,430

 

 

 

Provision for income taxes (e)

 

 

(128

)

 

 

 

 

(52

)

 

 

Equity in earnings/(losses) of unconsolidated entities

 

 

(84

)

 

 

 

 

(16

)

 

 

Net income

 

 

1,553

 

 

 

 

 

1,362

 

 

 

Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest

 

 

6

 

 

 

 

 

1

 

 

 

Net income attributable to Thermo Fisher Scientific Inc.

 

$

1,548

 

 

14.7

%

 

$

1,361

 

 

12.7

%

 

 

 

 

 

 

 

 

 

Earnings per share attributable to Thermo Fisher Scientific Inc.:

 

 

 

 

 

 

 

 

Basic

 

$

4.05

 

 

 

 

$

3.53

 

 

 

Diluted

 

$

4.04

 

 

 

 

$

3.51

 

 

 

Weighted average shares:

 

 

 

 

 

 

 

 

Basic

 

 

382

 

 

 

 

 

386

 

 

 

Diluted

 

 

383

 

 

 

 

 

388

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of adjusted operating income and adjusted operating margin

 

 

 

 

 

 

 

 

GAAP operating income

 

$

1,820

 

 

17.3

%

 

$

1,578

 

 

14.8

%

Cost of revenues adjustments (a)

 

 

1

 

 

0.0

%

 

 

18

 

 

0.2

%

Selling, general and administrative expenses adjustments (b)

 

 

(64

)

 

-0.6

%

 

 

6

 

 

0.1

%

Restructuring and other costs (c)

 

 

77

 

 

0.7

%

 

 

183

 

 

1.7

%

Amortization of acquisition-related intangible assets

 

 

513

 

 

4.9

%

 

 

585

 

 

5.4

%

Adjusted operating income (non-GAAP measure)

 

$

2,347

 

 

22.3

%

 

$

2,370

 

 

22.2

%

 

 

 

 

 

 

 

 

 

Reconciliation of adjusted net income

 

 

 

 

 

 

 

 

GAAP net income attributable to Thermo Fisher Scientific Inc.

 

$

1,548

 

 

 

 

$

1,361

 

 

 

Cost of revenues adjustments (a)

 

 

1

 

 

 

 

 

18

 

 

 

Selling, general and administrative expenses adjustments (b)

 

 

(64

)

 

 

 

 

6

 

 

 

Restructuring and other costs (c)

 

 

77

 

 

 

 

 

183

 

 

 

Amortization of acquisition-related intangible assets

 

 

513

 

 

 

 

 

585

 

 

 

Other income/expense adjustments (d)

 

 

 

 

 

 

 

(1

)

 

 

Provision for income taxes adjustments (e)

 

 

(102

)

 

 

 

 

(171

)

 

 

Equity in earnings/losses of unconsolidated entities

 

 

84

 

 

 

 

 

16

 

 

 

Noncontrolling interests adjustments (f)

 

 

(1

)

 

 

 

 

 

 

 

Adjusted net income (non-GAAP measure)

 

$

2,057

 

 

 

 

$

1,997

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of adjusted earnings per share

 

 

 

 

 

 

 

 

GAAP diluted EPS attributable to Thermo Fisher Scientific Inc.

 

$

4.04

 

 

 

 

$

3.51

 

 

 

Cost of revenues adjustments (a)

 

 

0.00

 

 

 

 

 

0.05

 

 

 

Selling, general and administrative expenses adjustments (b)

 

 

(0.17

)

 

 

 

 

0.01

 

 

 

Restructuring and other costs (c)

 

 

0.20

 

 

 

 

 

0.47

 

 

 

Amortization of acquisition-related intangible assets

 

 

1.34

 

 

 

 

 

1.51

 

 

 

Other income/expense adjustments (d)

 

 

0.00

 

 

 

 

 

0.00

 

 

 

Provision for income taxes adjustments (e)

 

 

(0.26

)

 

 

 

 

(0.44

)

 

 

Equity in earnings/losses of unconsolidated entities

 

 

0.22

 

 

 

 

 

0.04

 

 

 

Noncontrolling interests adjustments (f)

 

 

0.00

 

 

 

 

 

0.00

 

 

 

Adjusted EPS (non-GAAP measure)

 

$

5.37

 

 

 

 

$

5.15

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of free cash flow

 

 

 

 

 

 

 

 

GAAP net cash provided by operating activities

 

$

1,960

 

 

 

 

$

1,540

 

 

 

Purchases of property, plant and equipment

 

 

(301

)

 

 

 

 

(284

)

 

 

Proceeds from sale of property, plant and equipment

 

 

15

 

 

 

 

 

4

 

 

 

Free cash flow (non-GAAP measure)

 

$

1,674

 

 

 

 

$

1,260

 

 

 

Business Segment Information

 

Three months ended

 

 

June 29,

 

% of

 

July 1,

 

% of

(Dollars in millions)

 

2024

 

Revenues

 

2023

 

Revenues

 

 

 

 

 

 

 

 

 

Revenues

 

 

 

 

 

 

 

 

Life Sciences Solutions

 

$

2,355

 

 

22.3

%

 

$

2,463

 

 

23.0

%

Analytical Instruments

 

 

1,782

 

 

16.9

%

 

 

1,749

 

 

16.4

%

Specialty Diagnostics

 

 

1,117

 

 

10.6

%

 

 

1,109

 

 

10.4

%

Laboratory Products and Biopharma Services

 

 

5,758

 

 

54.6

%

 

 

5,831

 

 

54.6

%

Eliminations

 

 

(470

)

 

-4.5

%

 

 

(465

)

 

-4.4

%

Consolidated revenues

 

$

10,541

 

 

100.0

%

 

$

10,687

 

 

100.0

%

 

 

 

 

 

 

 

 

 

Segment income and segment income margin

 

 

 

 

 

 

 

 

Life Sciences Solutions

 

$

865

 

 

36.7

%

 

$

817

 

 

33.2

%

Analytical Instruments

 

 

439

 

 

24.6

%

 

 

432

 

 

24.7

%

Specialty Diagnostics

 

 

299

 

 

26.7

%

 

 

297

 

 

26.7

%

Laboratory Products and Biopharma Services

 

 

745

 

 

12.9

%

 

 

824

 

 

14.1

%

Subtotal reportable segments

 

 

2,347

 

 

22.3

%

 

 

2,370

 

 

22.2

%

Cost of revenues adjustments (a)

 

 

(1

)

 

0.0

%

 

 

(18

)

 

-0.2

%

Selling, general and administrative expenses adjustments (b)

 

 

64

 

 

0.6

%

 

 

(6

)

 

-0.1

%

Restructuring and other costs (c)

 

 

(77

)

 

-0.7

%

 

 

(183

)

 

-1.7

%

Amortization of acquisition-related intangible assets

 

 

(513

)

 

-4.9

%

 

 

(585

)

 

-5.4

%

Consolidated GAAP operating income

 

$

1,820

 

 

17.3

%

 

$

1,578

 

 

14.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a) Adjusted results in 2024 and 2023 exclude charges for inventory write-downs associated with large-scale abandonment of product lines. Adjusted results in 2023 exclude $11 of charges for the sale of inventory revalued at the date of acquisition and $5 of accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations.

(b) Adjusted results in 2024 and 2023 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, and charges/credits for changes in estimates of contingent acquisition consideration.

(c) Adjusted results in 2024 and 2023 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges for pre-acquisition litigation and other matters, and abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude $26 of contract termination costs associated with facility closures.

(d) Adjusted results in 2024 and 2023 exclude net gains/losses on investments.

(e) Adjusted results in 2024 and 2023 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes, and the tax impacts from audit settlements.

(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.

Note:

Consolidated depreciation expense is $276 and $270 in 2024 and 2023, respectively.

Organic and Core organic revenue growth

 

Three months ended

 

 

 

June 29, 2024

 

Revenue growth

 

-1 %

 

Acquisitions

 

0 %

 

Currency translation

 

-1 %

 

Organic revenue growth (non-GAAP measure)

 

-1 %

 

COVID-19 testing revenue

 

-1 %

 

Core organic revenue growth (non-GAAP measure)

 

0 %

 

 

 

 

 

Note:

 

For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.

 

Condensed Consolidated Statements of Income (unaudited)

 

 

 

 

 

 

 

 

 

 

Six months ended

 

 

June 29,

 

% of

 

July 1,

 

% of

(Dollars in millions except per share amounts)

 

2024

 

Revenues

 

2023

 

Revenues

Revenues

 

$

20,886

 

 

 

 

$

21,397

 

 

 

Costs and operating expenses:

 

 

 

 

 

 

 

 

Cost of revenues (a)

 

 

12,146

 

 

58.2

%

 

 

12,760

 

 

59.6

%

Selling, general and administrative expenses (b)

 

 

3,417

 

 

16.4

%

 

 

3,319

 

 

15.5

%

Amortization of acquisition-related intangible assets

 

 

1,065

 

 

5.1

%

 

 

1,191

 

 

5.5

%

Research and development expenses

 

 

670

 

 

3.2

%

 

 

691

 

 

3.2

%

Restructuring and other costs (c)

 

 

106

 

 

0.5

%

 

 

295

 

 

1.4

%

Total costs and operating expenses

 

 

17,404

 

 

83.3

%

 

 

18,256

 

 

85.3

%

Operating income

 

 

3,483

 

 

16.7

%

 

 

3,141

 

 

14.7

%

Interest income

 

 

574

 

 

 

 

 

324

 

 

 

Interest expense

 

 

(717

)

 

 

 

 

(626

)

 

 

Other income/(expense) (d)

 

 

14

 

 

 

 

 

(46

)

 

 

Income before income taxes

 

 

3,354

 

 

 

 

 

2,793

 

 

 

Provision for income taxes (e)

 

 

(408

)

 

 

 

 

(98

)

 

 

Equity in earnings/(losses) of unconsolidated entities

 

 

(61

)

 

 

 

 

(41

)

 

 

Net income

 

 

2,885

 

 

 

 

 

2,654

 

 

 

Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest

 

 

9

 

 

 

 

 

4

 

 

 

Net income attributable to Thermo Fisher Scientific Inc.

 

$

2,875

 

 

13.8

%

 

$

2,650

 

 

12.4

%

 

 

 

 

 

 

 

 

 

Earnings per share attributable to Thermo Fisher Scientific Inc.:

 

 

 

 

 

 

 

 

Basic

 

$

7.53

 

 

 

 

$

6.86

 

 

 

Diluted

 

$

7.50

 

 

 

 

$

6.83

 

 

 

Weighted average shares:

 

 

 

 

 

 

 

 

Basic

 

 

382

 

 

 

 

 

386

 

 

 

Diluted

 

 

383

 

 

 

 

 

388

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of adjusted operating income and adjusted operating margin

 

 

 

 

 

 

 

 

GAAP operating income

 

$

3,483

 

 

16.7

%

 

$

3,141

 

 

14.7

%

Cost of revenues adjustments (a)

 

 

17

 

 

0.1

%

 

 

59

 

 

0.3

%

Selling, general and administrative expenses adjustments (b)

 

 

(45

)

 

-0.2

%

 

 

14

 

 

0.1

%

Restructuring and other costs (c)

 

 

106

 

 

0.5

%

 

 

295

 

 

1.4

%

Amortization of acquisition-related intangible assets

 

 

1,065

 

 

5.1

%

 

 

1,191

 

 

5.5

%

Adjusted operating income (non-GAAP measure)

 

$

4,625

 

 

22.1

%

 

$

4,700

 

 

22.0

%

 

 

 

 

 

 

 

 

 

Reconciliation of adjusted net income

 

 

 

 

 

 

 

 

GAAP net income attributable to Thermo Fisher Scientific Inc.

 

$

2,875

 

 

 

 

$

2,650

 

 

 

Cost of revenues adjustments (a)

 

 

17

 

 

 

 

 

59

 

 

 

Selling, general and administrative expenses adjustments (b)

 

 

(45

)

 

 

 

 

14

 

 

 

Restructuring and other costs (c)

 

 

106

 

 

 

 

 

295

 

 

 

Amortization of acquisition-related intangible assets

 

 

1,065

 

 

 

 

 

1,191

 

 

 

Other income/expense adjustments (d)

 

 

(11

)

 

 

 

 

45

 

 

 

Provision for income taxes adjustments (e)

 

 

(51

)

 

 

 

 

(342

)

 

 

Equity in earnings/losses of unconsolidated entities

 

 

61

 

 

 

 

 

41

 

 

 

Noncontrolling interests adjustments (f)

 

 

(1

)

 

 

 

 

 

 

 

Adjusted net income (non-GAAP measure)

 

$

4,016

 

 

 

 

$

3,953

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of adjusted earnings per share

 

 

 

 

 

 

 

 

GAAP diluted EPS attributable to Thermo Fisher Scientific Inc.

 

$

7.50

 

 

 

 

$

6.83

 

 

 

Cost of revenues adjustments (a)

 

 

0.04

 

 

 

 

 

0.15

 

 

 

Selling, general and administrative expenses adjustments (b)

 

 

(0.12

)

 

 

 

 

0.03

 

 

 

Restructuring and other costs (c)

 

 

0.28

 

 

 

 

 

0.76

 

 

 

Amortization of acquisition-related intangible assets

 

 

2.78

 

 

 

 

 

3.07

 

 

 

Other income/expense adjustments (d)

 

 

(0.03

)

 

 

 

 

0.11

 

 

 

Provision for income taxes adjustments (e)

 

 

(0.13

)

 

 

 

 

(0.88

)

 

 

Equity in earnings/losses of unconsolidated entities

 

 

0.16

 

 

 

 

 

0.11

 

 

 

Noncontrolling interests adjustments (f)

 

 

0.00

 

 

 

 

 

0.00

 

 

 

Adjusted EPS (non-GAAP measure)

 

$

10.47

 

 

 

 

$

10.18

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of adjusted free cash flow

 

 

 

 

 

 

 

 

GAAP net cash provided by operating activities

 

$

3,211

 

 

 

 

$

2,269

 

 

 

Purchases of property, plant and equipment

 

 

(648

)

 

 

 

 

(742

)

 

 

Proceeds from sale of property, plant and equipment

 

 

20

 

 

 

 

 

10

 

 

 

Free cash flow (non-GAAP measure)

 

$

2,583

 

 

 

 

$

1,537

 

 

 

Business Segment Information

 

Six months ended

 

 

June 29,

 

% of

 

July 1,

 

% of

(Dollars in millions)

 

2024

 

Revenues

 

2023

 

Revenues

 

 

 

 

 

 

 

 

 

Revenues

 

 

 

 

 

 

 

 

Life Sciences Solutions

 

$

4,640

 

 

22.2

%

 

$

5,075

 

 

23.7

%

Analytical Instruments

 

 

3,469

 

 

16.6

%

 

 

3,472

 

 

16.2

%

Specialty Diagnostics

 

 

2,227

 

 

10.7

%

 

 

2,217

 

 

10.4

%

Laboratory Products and Biopharma Services

 

 

11,480

 

 

55.0

%

 

 

11,594

 

 

54.2

%

Eliminations

 

 

(930

)

 

-4.5

%

 

 

(961

)

 

-4.5

%

Consolidated revenues

 

$

20,886

 

 

100.0

%

 

$

21,397

 

 

100.0

%

 

 

 

 

 

 

 

 

 

Segment income and segment income margin

 

 

 

 

 

 

 

 

Life Sciences Solutions

 

$

1,705

 

 

36.7

%

 

$

1,653

 

 

32.6

%

Analytical Instruments

 

 

838

 

 

24.2

%

 

 

853

 

 

24.6

%

Specialty Diagnostics

 

 

593

 

 

26.6

%

 

 

577

 

 

26.0

%

Laboratory Products and Biopharma Services

 

 

1,489

 

 

13.0

%

 

 

1,617

 

 

14.0

%

Subtotal reportable segments

 

 

4,625

 

 

22.1

%

 

 

4,700

 

 

22.0

%

Cost of revenues adjustments (a)

 

 

(17

)

 

-0.1

%

 

 

(59

)

 

-0.3

%

Selling, general and administrative expenses adjustments (b)

 

 

45

 

 

0.2

%

 

 

(14

)

 

-0.1

%

Restructuring and other costs (c)

 

 

(106

)

 

-0.5

%

 

 

(295

)

 

-1.4

%

Amortization of acquisition-related intangible assets

 

 

(1,065

)

 

-5.1

%

 

 

(1,191

)

 

-5.5

%

Consolidated GAAP operating income

 

$

3,483

 

 

16.7

%

 

$

3,141

 

 

14.7

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a) Adjusted results in 2024 and 2023 exclude charges for inventory write-downs associated with large-scale abandonment of product lines and accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations. Adjusted results in 2023 exclude $21 of charges for the sale of inventory revalued at the date of acquisition.

(b) Adjusted results in 2024 and 2023 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, and charges/credits for changes in estimates of contingent acquisition consideration.

(c) Adjusted results in 2024 and 2023 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges for pre-acquisition litigation and other matters, and abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude $26 of contract termination costs associated with facility closures.

(d) Adjusted results in 2024 and 2023 exclude net gains/losses on investments.

(e) Adjusted results in 2024 and 2023 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements.

(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.

 

 

 

 

 

 

 

 

 

Notes:

Consolidated depreciation expense is $562 and $523 in 2024 and 2023, respectively.

For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.

Condensed Consolidated Balance Sheets (unaudited)

 

 

 

 

 

 

 

 

 

 

 

June 29,

 

December 31,

(In millions)

 

2024

 

2023

 

 

 

 

 

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

7,073

 

$

8,077

Short-term investments

 

 

1,750

 

 

3

Accounts receivable, net

 

 

7,943

 

 

8,221

Inventories

 

 

5,198

 

 

5,088

Other current assets

 

 

3,512

 

 

3,200

Total current assets

 

 

25,476

 

 

24,589

Property, plant and equipment, net

 

 

9,282

 

 

9,448

Acquisition-related intangible assets, net

 

 

15,519

 

 

16,670

Other assets

 

 

4,377

 

 

3,999

Goodwill

 

 

43,843

 

 

44,020

Total assets

 

$

98,496

 

$

98,726

 

 

 

 

 

Liabilities, redeemable noncontrolling interest and equity

 

 

 

 

Current liabilities:

 

 

 

 

Short-term obligations and current maturities of long-term obligations

 

$

5,121

 

$

3,609

Other current liabilities

 

 

9,651

 

 

10,403

Total current liabilities

 

 

14,772

 

 

14,012

Other long-term liabilities

 

 

5,907

 

 

6,564

Long-term obligations

 

 

30,284

 

 

31,308

Redeemable noncontrolling interest

 

 

115

 

 

118

Total equity

 

 

47,419

 

 

46,724

Total liabilities, redeemable noncontrolling interest and equity

 

$

98,496

 

$

98,726

Condensed Consolidated Statements of Cash Flows (unaudited)

 

 

 

 

 

 

 

 

 

 

 

Six months ended

 

 

June 29,

 

July 1,

(In millions)

 

2024

 

2023

 

 

 

 

 

Operating activities

 

 

 

 

Net income

 

$

2,885

 

 

$

2,654

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

 

1,626

 

 

 

1,714

 

Change in deferred income taxes

 

 

(607

)

 

 

(328

)

Other non-cash expenses, net

 

 

311

 

 

 

480

 

Changes in assets and liabilities, excluding the effects of acquisitions

 

 

(1,003

)

 

 

(2,251

)

Net cash provided by operating activities

 

 

3,211

 

 

 

2,269

 

 

 

 

 

 

Investing activities

 

 

 

 

Purchases of property, plant and equipment

 

 

(648

)

 

 

(742

)

Proceeds from sale of property, plant and equipment

 

 

20

 

 

 

10

 

Proceeds from cross-currency interest rate swap interest settlements

 

 

111

 

 

 

35

 

Acquisitions, net of cash acquired

 

 

 

 

 

(2,751

)

Purchases of investments

 

 

(1,778

)

 

 

(188

)

Other investing activities, net

 

 

12

 

 

 

51

 

Net cash used in investing activities

 

 

(2,283

)

 

 

(3,585

)

 

 

 

 

 

Financing activities

 

 

 

 

Net proceeds from issuance of debt

 

 

1,204

 

 

 

 

Repayment of debt

 

 

 

 

 

(1,000

)

Net proceeds from issuance of commercial paper

 

 

 

 

 

1,620

 

Repayment of commercial paper

 

 

 

 

 

(1,441

)

Purchases of company common stock

 

 

(3,000

)

 

 

(3,000

)

Dividends paid

 

 

(284

)

 

 

(252

)

Other financing activities, net

 

 

145

 

 

 

24

 

Net cash used in financing activities

 

 

(1,936

)

 

 

(4,049

)

 

 

 

 

 

Exchange rate effect on cash

 

 

7

 

 

 

(19

)

Decrease in cash, cash equivalents and restricted cash

 

 

(1,000

)

 

 

(5,384

)

Cash, cash equivalents and restricted cash at beginning of period

 

 

8,097

 

 

 

8,537

 

Cash, cash equivalents and restricted cash at end of period

 

$

7,097

 

 

$

3,153

 

 

 

 

 

 

Free cash flow (non-GAAP measure)

 

$

2,583

 

 

$

1,537

 

 

 

 

 

 

Note:

For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.

Supplemental Information Regarding Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of acquisitions/divestitures and the effects of currency translation. We also report Core organic revenue growth, which is reported revenue growth, excluding the impacts of COVID-19 testing revenue, and excluding the impacts of acquisitions/divestitures and the effects of currency translation. We report these measures because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures, foreign currency translation and/or COVID-19 testing on revenues. Thermo Fisher management uses these measures to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.

We report adjusted operating income, adjusted operating margin, adjusted net income, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:

  • Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
  • Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities are not indicative of our normal operating costs.
  • Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
  • The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
  • The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.

We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.

Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher Scientific’s results computed in accordance with GAAP.

The non-GAAP financial measures of Thermo Fisher Scientific’s results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher Scientific’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the tables above.

Media Contact Information:
Sandy Pound
Thermo Fisher Scientific
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com

Investor Contact Information:
Rafael Tejada
Thermo Fisher Scientific
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Source: Thermo Fisher Scientific Inc.

Multimedia Files:

View all news